50998-74-8 Usage
Description
2-[[(4-Methylphenyl)sulfonyl]amino]benzoic acid methyl ester is a chemical compound that belongs to the class of organic compounds known as benzoic acid esters. It is an ester derivative of benzoic acid with the molecular formula C15H15NO4S. 2-[[(4-Methylphenyl)sulfonyl]amino]benzoic acid methyl ester is widely used in synthetic organic chemistry for the preparation of complex molecules for pharmaceuticals, materials, and other applications. Its properties, such as solubility and reactivity, can vary significantly depending on factors like pH, temperature, and the presence of other chemicals.
Uses
Used in Pharmaceutical Industry:
2-[[(4-Methylphenyl)sulfonyl]amino]benzoic acid methyl ester is used as a key intermediate in the synthesis of various pharmaceutical compounds. Its unique chemical structure allows for the development of new drugs with potential therapeutic applications.
Used in Material Science:
In the field of material science, 2-[[(4-Methylphenyl)sulfonyl]amino]benzoic acid methyl ester is used as a building block for the creation of novel materials with specific properties. Its reactivity and solubility characteristics make it suitable for the synthesis of advanced materials with applications in various industries.
Used in Synthetic Organic Chemistry:
2-[[(4-Methylphenyl)sulfonyl]amino]benzoic acid methyl ester is used as a versatile reagent in synthetic organic chemistry. Its ability to react with a wide range of other chemicals enables the synthesis of complex organic molecules for various applications, including the development of new pharmaceuticals, agrochemicals, and specialty chemicals.
Used in Research and Development:
In research and development, 2-[[(4-Methylphenyl)sulfonyl]amino]benzoic acid methyl ester is utilized as a valuable tool for studying the properties and reactions of benzoic acid esters. Its unique structure and reactivity provide insights into the behavior of similar compounds, contributing to the advancement of organic chemistry and related fields.
Check Digit Verification of cas no
The CAS Registry Mumber 50998-74-8 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 5,0,9,9 and 8 respectively; the second part has 2 digits, 7 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 50998-74:
(7*5)+(6*0)+(5*9)+(4*9)+(3*8)+(2*7)+(1*4)=158
158 % 10 = 8
So 50998-74-8 is a valid CAS Registry Number.
InChI:InChI=1/C15H15NO4S/c1-11-7-9-12(10-8-11)21(18,19)16-14-6-4-3-5-13(14)15(17)20-2/h3-10,16H,1-2H3
50998-74-8Relevant articles and documents
Iridium-Catalyzed Cycloisomerization of Alkynoic Acids: Synthesis of Unsaturated Lactones
Huang, Yi,Zhang, Xianghe,Dong, Xiu-Qin,Zhang, Xumu
supporting information, p. 782 - 788 (2020/01/08)
The iridium-catalyzed cycloisomerization of various alkynoic acids was successfully developed, and a series of five-, six-, and especially seven-membered unsaturated lactones were constructed with moderate yields and excellent regioselectivities (up to 68
Gold promoted arylative cyclization of alkynoic acids with arenediazonium salts
Carrillo-Arcos, Ulises A.,Porcel, Susana
, p. 1837 - 1842 (2018/03/23)
Alkynoic acids derived from salicylic acid and analogues undergo arylative cyclization with arenediazonium salts promoted by gold in the absence of external ligands. The reaction is thermally induced and proceeds even in the absence of light. A difference in regioselectivity has been found compared with that observed in the cycloisomerization process of the same type of compounds.
LIT-001, the First Nonpeptide Oxytocin Receptor Agonist that Improves Social Interaction in a Mouse Model of Autism
Frantz, Marie-Céline,Pellissier, Lucie P.,Pflimlin, Elsa,Loison, Stéphanie,Gandiá, Jorge,Marsol, Claire,Durroux, Thierry,Mouillac, Bernard,Becker, Jér?me A. J.,Le Merrer, Julie,Valencia, Christel,Villa, Pascal,Bonnet, Dominique,Hibert, Marcel
, p. 8670 - 8692 (2018/10/05)
Oxytocin (OT) and its receptor (OT-R) are implicated in the etiology of autism spectrum disorders (ASD), and OT-R is a potential target for therapeutic intervention. Very few nonpeptide oxytocin agonists have currently been reported. Their molecular and in vivo pharmacology remain to be clarified, and none of them has been shown to be efficient in improving social interaction in animal models relevant to ASD. In an attempt to rationalize the design of centrally active nonpeptide full agonists, we studied in a systematic way the structural determinants of the affinity and efficacy of representative ligands of the V1a and V2 vasopressin receptor subtypes (V1a-R and V2-R) and of the oxytocin receptor. Our results confirm the subtlety of the structure-affinity and structure-efficacy relationships around vasopressin/oxytocin receptor ligands and lead however to the first nonpeptide OT receptor agonist active in a mouse model of ASD after peripheral ip administration.